3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
24
Carboplatin
21
Paclitaxel
20
olaparib
19
Magnetic Resonance Spectroscopy
14
Bevacizumab
14
Cyclophosphamide
12
Specimen Handling
11
Nivolumab
11
Gemcitabine
11
Taxes
10
niraparib
8
Cisplatin
8
Biopsy
8
liposomal doxorubicin
7
fludarabine
7
Surveys and Questionnaires
6
Immunoglobulin G
6
Doxorubicin
6
Disulfides
6
durvalumab
5
palbociclib
4
oregovomab
4
X-Rays
4
Ipilimumab
4
mirvetuximab soravtansine
3
ipatasertib
3
defactinib
3
cediranib
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ovarian Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled